6826.HK लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 12:26):

Stats
आज की मात्रा	28 400.00
औसत मात्रा	131 991
बाजार मूल्य	15.96B
EPS	HKD0 ( 2023-10-25 )
Last Dividend	HKD0.441 ( 2023-07-04 )
Next Dividend	HKD0 ( N/A )
P/E	15.81
ATR14	HKD0.0940 (0.23%)

मात्रा सहसंबंध

लंबा: 0.01 (neutral)

छोटा: -0.15 (neutral)

Signal:(52.807) Neutral

Shanghai Haohai सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Shanghai Haohai सहसंबंध - मुद्रा/वस्त्र

0.11
( neutral )

0.31
( neutral )

-0.30
( neutral )

0.27
( neutral )

0.07
( neutral )

Shanghai Haohai वित्तीय

Annual	2023
राजस्व:	HKD2.63B
सकल लाभ:	HKD1.85B (70.34 %)
EPS:	HKD2.44

FY	2023
राजस्व:	HKD2.63B
सकल लाभ:	HKD1.85B (70.34 %)
EPS:	HKD2.44

FY	2022
राजस्व:	HKD2.10B
सकल लाभ:	HKD1.45B (68.79 %)
EPS:	HKD1.040

FY	2021
राजस्व:	HKD1.75B
सकल लाभ:	HKD1.26B (71.98 %)
EPS:	HKD2.16

Financial Reports:

No articles found.

Shanghai Haohai Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.820 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.441 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Shanghai Haohai Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.27 - Stable (5.44%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.472	2016-06-08
Last Dividend	HKD0.441	2023-07-04
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	HKD4.88	--
Avg. Dividend % Per Year	0.00%	--
Score	3.11	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.27
Div. Directional Score	8.44	--

Next Divdend (Est)
(2024-07-12)

HKD0.326 Estimate 3.10 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.11

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2628.HK	Ex Dividend Junior	2023-07-05	Annually	0.00%
1408.HK	Ex Dividend Junior	2023-05-30	Annually	0.00%
0489.HK	No Dividend Player	2023-06-23	Annually	0.00%
6837.HK	No Dividend Player	2023-06-30	Annually	0.00%
1958.HK	Ex Dividend Junior	2023-06-28	Annually	0.00%
0991.HK	Ex Dividend Junior	2023-06-30	Sporadic	0.00%
0101.HK	Ex Dividend Junior	2023-09-12	Semi-Annually	0.00%
3328.HK	Ex Dividend Knight	2023-07-04	Annually	0.00%
1568.HK	Ex Dividend Junior	2023-06-05	Annually	0.00%
0596.HK	Ex Dividend Junior	2023-06-30	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.158	1.500	6.84	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0586	1.200	8.05	9.66	[0 - 0.3]
returnOnEquityTTM	0.0731	1.500	-0.299	-0.449	[0.1 - 1]
payoutRatioTTM	0.00486	-1.000	9.95	-9.95	[0 - 1]
currentRatioTTM	5.24	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.47	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	3.83	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0574	-1.500	9.04	-10.00	[0 - 0.6]
interestCoverageTTM	126.75	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	3.72	2.00	8.76	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.15	2.00	8.92	10.00	[0 - 20]
debtEquityRatioTTM	0.0722	-1.500	9.71	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.703	1.000	1.609	1.609	[0.2 - 0.8]
operatingProfitMarginTTM	0.174	1.000	8.51	8.51	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.555	1.000	2.47	2.47	[0.2 - 2]
assetTurnoverTTM	0.371	0.800	-0.861	-0.689	[0.5 - 2]
Total Score				11.61

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	15.47	1.000	8.54	0	[1 - 100]
returnOnEquityTTM	0.0731	2.50	-0.192	-0.449	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.15	2.00	9.28	10.00	[0 - 30]
dividendYielPercentageTTM	1.169	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.72	2.00	8.76	10.00	[0 - 30]
payoutRatioTTM	0.00486	1.500	9.95	-9.95	[0 - 1]
pegRatioTTM	0.318	1.500	-1.211	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.241	1.000	6.48	0	[0.1 - 0.5]
Total Score				5.27

Shanghai Haohai

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, scalpels, etc.; orthopedics products, such as sodium hyaluronate injection and medical chitosan; wound repair products, including recombinant human epidermal growth factor for the treatment of burn wound, residual wound, donor site posttraumatic wound, and fresh or old wound of chronic ulcer; anti-adhesion materials comprising medical sodium hyaluronate gel and medical chitosan; and hemostatic materials, such as collagen sponge and porcine fibrin sealants. The company also provides medical aesthetics products comprising Matrifill, a first-generation HA dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; and radio frequency devices and laser equipment. In addition, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; and investment and trading business. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.